Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRPH-222 in Relapsed/Refractory B-Cell Lymphoma
NCT03682796Phase 1Completed
- Sponsor
- Triphase Research and Development III Corp.
- Start
- Oct 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of trph-222 in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Triphase Research and Development III Corp. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Oct 2018; status: completed.
02
Drugs
trph-222
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03682796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682796.